A phase 2 basket trial testing oral ponatinib in solid tumors with genomic FGFR alterations did not meet its primary endpoint. The study reported disease control in some participants despite the overall failure to reach the predefined efficacy threshold. The result narrows expectations for ponatinib as a genotype-selected option in FGFR-altered solid tumors and sets a clear bar for whether future studies will reframe patient selection, dosing, or combination strategies. For developers targeting kinase pathways, the trial highlights the recurring challenge of translating biomarker-defined susceptibility into measurable clinical benefit.